ALK rearrangements are uncommon but actionable oncogenic drivers in non–small cell lung cancer.
|Articles|September 1, 2016
ONCOLOGY Cartoon Caption Contest
Leave your caption idea in the comment section for the chance to have your caption featured in an upcoming issue of ONCOLOGY.
Advertisement
Leave your caption idea in the comment section for the chance to have your caption featured in an upcoming issue of ONCOLOGY.
Advertisement
Related to this article
Although shortages periodically capture national attention when widely used agents such as cisplatin or carboplatin become scarce, the problem extends well beyond any single drug.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves sNDA for Taletrectinib in TKI-Naive Advanced ROS1+ NSCLC
2
IASO208 Receives FDA IND Clearance for Relapsed/Refractory B-Cell Lymphoma
3
SOHO 2026: Key Updates Across the Multiple Myeloma Continuum
4
PALOMA-2 Shows Improved Survival vs Historical IV Amivantamab Data
5